Thus, our data suggest that AREG represents one of the major TME‐derived soluble factors and precisely reflects the development of an in vivo SASP, and thus can be exploited to assess the magnitude of the SASP in cancer patients after clinical therapy. This evidence concerns the gene AREG and cancer.